Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inolimomab in Pediatric Steroid-Resistant Acute GvHD
NCT04289103Phase 3Unknown
- Sponsor
- ElsaLys Biotech
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of inolimomab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by ElsaLys Biotech. Primary endpoint: Overall response at Day 29. Status: unknown.
02
Drugs
inolimomab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04289103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04289103.